Phesgo 60,60 mg/ml Solution for Injection 10ml Vial

Phesgo is a groundbreaking fixed-dose combination of pertuzumab and trastuzumab, specifically formulated for subcutaneous injection, representing a significant advancement in HER2-positive breast cancer treatment. This innovative medication offers a convenient and effective therapeutic option, reducing administration time compared to traditional intravenous infusions. Phesgo is designed to target and block HER2 receptors, which are overexpressed in certain aggressive breast cancers, thereby inhibiting cancer cell growth and proliferation. It is an essential component of a comprehensive treatment regimen for eligible patients, ensuring high-quality care with improved patient experience.

Benefits of Use

• Highly effective targeted therapy for HER2-positive breast cancer.
• Convenient subcutaneous administration, significantly reducing clinic time compared to IV infusions.
• Combines two potent anti-HER2 antibodies (pertuzumab and trastuzumab) in one injection.
• Aids in improving progression-free survival and overall survival rates in eligible patients.
• Designed to provide consistent and reliable therapeutic levels of both active ingredients.

How to Use

1. Phesgo is administered by a healthcare professional in a clinical setting.
2. The recommended dose is administered subcutaneously in the thigh.
3. The initial loading dose is typically followed by maintenance doses administered every three weeks.
4. Patients should be monitored for infusion-related reactions during and after administration.
5. Do not self-administer Phesgo; always seek professional medical guidance.

Caution & Warnings

• Administer under the supervision of a healthcare professional experienced in the administration of anticancer agents.
• Cardiotoxicity: Monitor left ventricular ejection fraction (LVEF) before and during treatment. Phesgo can cause LVEF decrease and congestive heart failure.
• Embryo-Fetal Toxicity: Phesgo can cause fetal harm when administered to a pregnant woman. Advise women of reproductive potential of the potential risk to a fetus and to use effective contraception.
• Pulmonary Toxicity: Interstitial lung disease and pneumonitis have been reported.
• Hypersensitivity Reactions/Anaphylaxis: Serious hypersensitivity reactions have been observed. Appropriate medical care should be available.
• Not indicated for intravenous administration. Ensure correct subcutaneous route of administration.
• Report any adverse reactions immediately to your healthcare provider.

Ingredients

Each 10 ml single-dose vial of Phesgo contains:

• Pertuzumab: 600 mg (60 mg/ml)
• Trastuzumab: 600 mg (60 mg/ml)

Product Details

• Brand: Phesgo
• Manufacturer: Roche
• Form: Solution for Injection
• Strength: 600 mg Pertuzumab / 600 mg Trastuzumab (60 mg/ml each)
• Volume: 10 ml per vial
• Drug Type: Prescription Only Medicine (POM)
• Storage: Refrigerate at 2°C - 8°C. Do not freeze.